Smith & Nephew SNATS (NYSE:SNN) Lowered to “Hold” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Smith & Nephew SNATS (NYSE:SNN) from a buy rating to a hold rating in a research report sent to investors on Sunday.

A number of other research analysts also recently issued reports on SNN. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Smith & Nephew SNATS in a research report on Thursday, August 6th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Smith & Nephew SNATS in a report on Monday, May 25th. Zacks Research lowered Smith & Nephew SNATS from a “hold” rating to a “strong sell” rating in a report on Friday, August 7th. Kepler Capital Markets downgraded Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a research note on Thursday, June 4th. Finally, Morgan Stanley reiterated an “overweight” rating on shares of Smith & Nephew SNATS in a research note on Wednesday, August 5th. Two equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $30.93.

Smith & Nephew SNATS Price Performance

Shares of NYSE:SNN opened at $29.84 on Friday. The company has a current ratio of 2.14, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62. Smith & Nephew SNATS has a 12-month low of $28.56 and a 12-month high of $38.79. The business’s fifty day simple moving average is $30.45 and its 200-day simple moving average is $32.01.

Smith & Nephew SNATS Dividend Announcement

The company also recently declared a dividend, which will be paid on Friday, November 6th. Shareholders of record on Friday, October 2nd will be paid a dividend of $0.312 per share. This represents a yield of 205.0%. The ex-dividend date is Friday, October 2nd.

Institutional Trading of Smith & Nephew SNATS

Several large investors have recently made changes to their positions in SNN. Clearstead Trust LLC purchased a new position in shares of Smith & Nephew SNATS during the second quarter worth $25,000. Garner Asset Management Corp acquired a new position in Smith & Nephew SNATS during the fourth quarter valued at $27,000. Arax Advisory Partners boosted its holdings in Smith & Nephew SNATS by 142.6% in the fourth quarter. Arax Advisory Partners now owns 968 shares of the medical equipment provider’s stock valued at $32,000 after purchasing an additional 569 shares during the last quarter. Advisors Asset Management Inc. purchased a new stake in Smith & Nephew SNATS in the fourth quarter valued at $36,000. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in Smith & Nephew SNATS in the third quarter valued at $41,000. 25.64% of the stock is owned by hedge funds and other institutional investors.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.